Biocartis Group NV announced that Biocartis and Genomic Health, Inc. have agreed to terminate their collaboration, which was focused on the development of the Oncotype DX Breast Recurrence Score® test on Biocartis' molecular diagnostics platform Idylla. As a result of COVID-19, the project had been suspended earlier during 2020, with the project plan and timing under evaluation. The decision to now terminate the collaboration was driven by the uncertain timing of a product market release because of the pandemic and a decision by Exact Sciences to shift priorities to other initiatives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.08M | |
+73.17% | 12.38B | |
-18.74% | 7.92B | |
+16.15% | 7.2B | |
+4.81% | 5.84B | |
+5.99% | 5.01B | |
+27.07% | 4.53B | |
-21.67% | 3.88B | |
-40.82% | 2.23B | |
+1.49% | 2.02B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances